Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when Integra Lifesciences Holdings Corp publishes a filing, an earnings call transcript or a press release.

Get IART alerts

About Mojdeh Poul

Mojdeh Poul is recorded as Board Member at Integra Lifesciences Holdings Corp (IART) since January 6, 2025 and CEO at Integra Lifesciences Holdings Corp (IART). The newest filing on record that lists Mojdeh Poul as CEO at Integra Lifesciences Holdings Corp (IART) is dated April 6, 2026. Integra Lifesciences Holdings Corp reported in an 8-K filed May 5, 2026 that Mojdeh Poul resigned as member of the Company's Board of Directors, effective April 30, 2026. Integra Lifesciences Holdings Corp reported in an 8-K filed November 4, 2024 that Mojdeh Poul was appointed director, effective January 6, 2025. Integra Lifesciences Holdings Corp reported in an 8-K filed November 4, 2024 that Mojdeh Poul was appointed President and Chief Executive Officer, effective January 6, 2025. The proxy statement of Integra Lifesciences Holdings Corp reports total compensation of $9,375,551 for Mojdeh Poul in fiscal 2025, including a base salary of $1,009,616. Mojdeh Poul has spoken on 5 earnings calls across 1 company, most recently for Integra Lifesciences Holdings Corp on February 26, 2026. Integra Lifesciences Holdings Corp is classified in the Medical Devices industry within the Healthcare sector. Other leadership on record at Integra Lifesciences Holdings Corp includes Dr. Stuart M. Essig (CEO), Stuart M. Essig (CEO and Chairman), Stuart Essig (Chairman) and 7 others.

“Dr. Essig succeeds Mojdeh Poul, who is departing from her role as the Company’s President and Chief Executive Officer and as a member of the Company’s Board of Directors (the “Board”) effective as of the end of the day on April 30, 2026 (the “Separation Date”).”
Integra Lifesciences Holdings Corp Form 8-K, filed May 5, 2026 · Read the filing
“In connection with her appointment as President and Chief Executive Officer of the Company, the Board of Directors of the Company (the “Board”) also appointed Ms. Poul as a director of the Board effective with the commencement of her employment, with her term expiring at the Company’s 2025 annual meeting of stockholders.”
Integra Lifesciences Holdings Corp Form 8-K, filed November 4, 2024 · Read the filing

Mojdeh Poul on recent calls

“Good morning, everyone, and thank you for joining us for our fourth quarter 2025 earnings call. Before I review our 2025 performance and outline our priorities for 2026, I want to briefly acknowledge the recent Supreme Court decision and the administration's announcement regarding new Section 122 tariffs.”
CEO, Integra Lifesciences Holdings Corp Q4 FY2025 Earnings Call ·
“Good morning, everyone, and thank you for joining us for our third quarter 2025 earnings call. During today's call, I will begin with an overview of our third quarter results.”
CEO, Integra Lifesciences Holdings Corp Q3 FY2025 Earnings Call ·
“Good morning, everyone, and thank you for joining us for our second quarter 2025 earnings call. I would like to start by acknowledging the tremendous work done by our teams across the company to deliver a strong second quarter performance while advancing our priorities.”
CEO, Integra Lifesciences Holdings Corp Q2 FY2025 Earnings Call ·
“During today's call, I will provide a brief overview of our operating results for the first quarter followed by an update on our compliance master plan, new initiatives, and key leadership appointments that will strengthen our operations, overall execution and enterprise discipline.”
CEO, Integra Lifesciences Holdings Corp Q1 FY2025 Earnings Call ·
“Before we begin, I want to take a moment to recognize and thank our employees around the world. Over the past several months, our teams have navigated challenges with dedication and resilience, staying focused on delivering for our customers and patients.”
CEO, Integra Lifesciences Holdings Corp Q4 FY2024 Earnings Call ·

Affiliation history

Company network

Leadership on record at Integra Lifesciences Holdings Corp

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 Integra Lifesciences Holdings Corp (IART) $1,009,616 $9,375,551

Recent activity